Answers are grounded in this paper and cite their sources.
Intratumor heterogeneity is a hallmark of hepatocellular carcinoma (HCC) that contributes to therapy resistance and poor clinical outcomes. Using patient-derived HCC organoids (HCCOs), we examine whether this diversity can be regenerated from single tumor cells. Across nine HCCO lines, a large proportion of individual cells give rise to new organoids, indicating that clonogenic capacity is broadly distributed rather than confined to a rare subset. Single-cell-derived HCCOs (scd-HCCOs) regenerate heterogeneous marker expression and display variable proliferation and drug responses. Single-cell RNA sequencing shows that parental and clonal organoids share a common repertoire of transcriptional states, with individual scd-HCCOs differing mainly in the relative abundance of these states. Serial single-cell cloning shows that functional traits diversify again in each generation, and whole-exome sequencing reveals few new point mutations but substantial copy-number variation. Single HCC cells therefore regenerate the marker, transcriptional, and functional diversity of the organoids they derive from.
No takes yet. Share an insight, caveat, or question.
Kübler et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: